Zydus Lifesciences reports robust Q2 FY26 growth, strong revenue and profit gains

Zydus Lifesciences reported robust Q2 FY26 results, with total revenues increasing by 17% year-over-year (YoY) to Rs. 61,232 mn. The company's EBITDA rose by 37.9% YoY to Rs. 20,158 mn, achieving a margin of 32.9%. Net profit for the quarter also saw a substantial increase of 38% YoY, reaching Rs. 12,586 mn. India's branded formulations outpaced market growth with a 9% YoY increase, supported by innovation products and pillar brands.

The US formulations business recorded strong double-digit YoY growth (13.5%), fueled by volume expansion and new product launches, including seven new products and approval for four ANDAs. Notably, the company launched Beizray (albumin solubilized docetaxel injection) in October 2025, strengthening its 505(b)(2) portfolio. Additionally, the Consumer Wellness business made its first international acquisition by acquiring UK-based Comfort Click Ltd (CCL).

In regulatory news, the oncology injectable manufacturing facility in SEZ1, Ahmedabad, and the Baddi formulations facility received Establishment Inspection Reports (EIR) with Voluntary Action Indicated (VAI) status from the USFDA. Zydus Lifesciences also received regulatory approval to initiate Phase II clinical trials for a Bivalent Typhoid Conjugate Vaccine in India and reported positive topline results for Saroglitazar Magnesium in patients with PBC for the US market.